Clinical Decision Support to Implement CYP2D6 Drug-Gene Interaction.
The level of CYP2D6 metabolic activity can be predicted by pharmacogenomic testing, and concomitant use of clinical decision support has the potential to prevent adverse effects from those drugs metabolized by this enzyme. Our initial findings after implementation of clinical decision support alerts integrated in the electronic health records suggest high feasibility, but also identify important challenges.
Mayo Clinic, Rochester, Minnesota, USA.
Pedro J
PJ
Caraballo
Mayo Clinic, Rochester, Minnesota, USA.
Mark
M
Parkulo
Mayo Clinic, Rochester, Minnesota, USA.
David
D
Blair
Mayo Clinic, Rochester, Minnesota, USA.
Michelle
M
Elliott
Mayo Clinic, Rochester, Minnesota, USA.
Cloann
C
Schultz
Mayo Clinic, Rochester, Minnesota, USA.
Joseph
J
Sutton
Mayo Clinic, Rochester, Minnesota, USA.
Padma
P
Rao
Mayo Clinic, Rochester, Minnesota, USA.
Jamie
J
Bruflat
Mayo Clinic, Rochester, Minnesota, USA.
Robert
R
Bleimeyer
Mayo Clinic, Rochester, Minnesota, USA.
John
J
Crooks
Mayo Clinic, Rochester, Minnesota, USA.
Donald
D
Gabrielson
Mayo Clinic, Rochester, Minnesota, USA.
Wayne
W
Nicholson
Mayo Clinic, Rochester, Minnesota, USA.
Carolyn
C
Rohrer Vitek
Mayo Clinic, Rochester, Minnesota, USA.
Kelly
K
Wix
Mayo Clinic, Rochester, Minnesota, USA.
Suzette J
SJ
Bielinski
Mayo Clinic, Rochester, Minnesota, USA.
Jyotishman
J
Pathak
Mayo Clinic, Rochester, Minnesota, USA.
Iftikhar
I
Kullo
D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D020000:Decision Support Systems, Clinical; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control; D057286:Electronic Health Records; D006801:Humans; D050316:Medical Order Entry Systems; D010597:Pharmacogenetics / Q000379:methods; D016730:Program Development
D019389:Cytochrome P-450 CYP2D6